We’ll soon be trading hard hats and vests for clean room gowns! 👷👩🔬 We were delighted to show The Hon Ben Carroll MP, Deputy Premier of Victoria and Minister for Medical Research, around our shiny new state-of-the-art cell-based influenza vaccine and antivenom manufacturing facility in Tullamarine. The construction phase is ending and the qualification phase is set to begin on this landmark facility which will boost CSL Seqirus’ global manufacturing network and Australia’s sovereign capability for #vaccine production. #CSL #CSLSeqirus #DrivenByOurPromise #AustralianMade #AustralianManufacuring #PublicHealth #Influenza #Tullamarine
About us
CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
- Website
-
https://www.csl.com/
External link for CSL
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Melbourne, Victoria
- Type
- Public Company
- Specialties
- Complex biologicals, vaccines, plasma and plasma derived therapeutics, and biotechnology
Locations
-
Primary
655 Elizabeth St
Melbourne, Victoria 3000, AU
-
1020 1st Ave
King of Prussia, PA 19406, US
Employees at CSL
Updates
-
Together, we create breakthroughs. At CSL, collaboration is at the heart of everything we do. By working together across teams and disciplines, we bring innovative treatments to patients in need. www.csl.com #CSL #values
-
Meet Lena Rengifo, our Facility Coordination Officer at CSL Broadmeadow’s Facility F. Get a glimpse of her role in fractionation and how it’s pivotal in producing CSL’s therapeutic products. Discover the collaborative spirit and diversity that drive innovation at CSL. Lena’s journey reflects our commitment to making a global impact on people’s lives. Learn more https://bit.ly/4cI2rjZ #PromisingFutures #CSL #DoWhatThatMatters
-
Here at CSL, we have been celebrating NAIDOC Week and this year’s theme of ‘Keep the Fire Burning! Blak, Loud and Proud’. In one of our sessions this week, we talked about the 2015 song by Briggs (feat. Dr G Yunupingu and Dewayne Everettsmith) – The Children Came Back. We are sharing it today as it encapsulates the intention of NAIDOC Week, celebrating First Nations culture and achievements, and recognising history. #NAIDOCWeek #NAIDOC2024 https://lnkd.in/dEtjt96x 📸 credit Jeffrey Spicer
-
-
We are proud to have sponsored this year's HTAi Annual Conference in Seville, where over 100 HTA agencies and 1000+ attendees from around the globe gathered to discuss the latest trends and innovations in Health Technology Assessment (HTA). For the first time, we also sponsored a CSL symposium on "Managing Uncertainty in Decision-Making: Enabling Patient Access to Innovation" featuring insights from top experts like Prof. Alberto Corsini, Dr. James Fotheringham, and Dr. Jani Mueller. Special thanks to our Jie Shen, Global Head of Market Access, and her incredible team for their strategic work. At CSL we are looking forward to continued collaboration and partnership with HTA agencies worldwide. Together, we can work together to drive innovation, value and timely patient access, enabling us to deliver the maximum benefits for patients around globally. Find out more about CSL and our activities here: https://bit.ly/4bBonvH #HTAi2024 #HealthcareInnovation #HTA #MarketAccess #CSLVifor #PatientCentricity #RealWorldEvidence #EUHTA
-
-
Major life changes can be challenging, especially for young adults with chronic diseases. #PatientStories In this Vita article, we discuss how to prepare for college when you have a primary immunodeficiency: https://bit.ly/4bxvndb
-
-
To support healthcare providers and consumers as we head into this #flu season, CSL Seqirus, CSL’s vaccine business unit, has begun shipping its portfolio of influenza vaccines for the 2024/25 season. Recent trends show a significant decline in the number of people receiving their flu shots, which is concerning for public health as vaccinations are crucial in helping prevent the spread of #influenza and protecting our communities. The Centers for Disease Control and Prevention (CDC) recommends that all eligible individuals 6 months and older get their annual flu vaccine to help stay safe and protect others, including if they're 65 or over, pregnant, or if they live with or care for someone at higher risk of serious influenza complications. We share the CDC’s view that vaccination is important and are committed to doing our part throughout the upcoming season to help people and communities stay healthy. For more information, please see here: https://bit.ly/3VZFP7g #CSL #CSLSeqirus #DrivenByOurPromise #Vaccination #PublicHealth
-